🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

AbbVie cuts 2024 profit forecast citing R&D expenses

Published 10/03/2024, 04:16 PM
Updated 10/03/2024, 04:35 PM
© Reuters. FILE PHOTO: Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
ABBV
-

(Reuters) -AbbVie on Thursday lowered its forecast for 2024 adjusted profit, citing the impact of $82 million in milestones, and research and development expenses related to acquisitions.

The drugmaker expects annual adjusted profit per share in the range of $10.67 to $10.87, compared with its previous forecast of $10.71 to $10.91 per share, a regulatory filing showed.

Analysts were expecting $10.88 per share, according to estimates compiled by LSEG.

AbbVie (NYSE:ABBV) also cut its forecast for third-quarter adjusted profit per share to $2.88 to $2.92 from $2.92 to $2.96 previously.

© Reuters. FILE PHOTO: Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

The company said it incurred $82 million in expenses during the quarter related to collaborations, licensing agreements and other asset acquisitions.

AbbVie is scheduled to report third-quarter results on Oct. 30.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.